Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

806.05 -12.88 (-1.57%)
Streaming Delayed Price Updated: 3:46 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher 
Via MarketBeat
Exposures Product Safety
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras
Costco's new weight loss initiative, in partnership with Sesame, a healthcare marketplace, will offer members a three-month clinical consultation and other services for $179. 
Via Benzinga
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
What Analysts Are Saying About Eli Lilly and Co Stock
Via Benzinga
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand
Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity... 
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Eli Lilly's stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors. 
Via Benzinga
Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action
Several leading stocks are finding support around the 10-week line, creating potential buying opportunities. 
Via Investor's Business Daily
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Buy Amazon Stock Now for Continued Growth and Diversification
Year to date, Amazon's share price is up 20%, nearly double the 11% gain in the benchmark S&P 500 index. Over the last 12 months, Amazon stock has gained 75%. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Could Viking Therapeutics Stock Be a Millionaire Maker?
There is a plausible path for this biotech stock to make some investors millionaires. 
Via The Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area. 
Via The Motley Fool
Top Stock Reports For Apple, Nvidia & Eli Lilly
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., NVIDIA Corporation, and Eli Lilly and Company. 
Via Talk Markets
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
All three companies have very long runways for growth ahead. 
Via The Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
2 Top Biotech Buyout Candidates
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond
Great companies in steadily growing industries can deliver enviable returns through the years. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects. 
Via The Motley Fool
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1?
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried about the sustainability of the uptrend. 
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
Via Benzinga
Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?
Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first. 
Via The Motley Fool
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.